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Abstract 
 
In the last few decades the introduction of bioactive glasses, a special class of bioceramics that are 
able to bond to living tissues stimulating new tissue growth, has improved both treatment 
procedures via reconstructive surgery and the quality of life of rehabilitated patients in orthopaedics 
and dentistry. While bioactive glasses have been extensively investigated for applications in these 
two surgical fields, there has been relatively little research on their use in other medical areas. Glass 
has been used for centuries to produce external refractive lenses and the intraocular implantation of 
small glass disks to correct visual deficiencies has been documented since the mid 1700s. 
Moreover, some evidences reported in the recent literature seem to demonstrate that the success of 
three specific types of ophthalmic devices, i.e. synthetic grafts for eye orbit bone repair, orbital 
implants replacing the whole ocular globe and keratoprostheses (artificial cornea), could 
significantly benefit by the use of bioactive glass. A prospective view as well as a state-of-the-art 
review on this topic are currently lacking in the literature. The present article aims to give a 
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comprehensive picture of the bioactive glass-based implants that have been developed in the 
context of ocular surgery; the strengths and shortcomings of the existing devices are outlined in 
order to provide useful stimuli for future research. Promising research directions are also proposed, 
emphasizing the added values that bioactive glasses could carry in ophthalmology in the light of 
recent findings in tissue engineering and regenerative medicine.  
 
Keywords: Bioactive glass; Eye orbit; Artificial cornea; Tissue integration; Angiogenesis. 
 
INTRODUCTION 
 
Glass had and currently still has a great importance in ophthalmology due to a number of attractive 
features, including transparency to visible light, biocompatibility and relative ease of processing; it 
is commonly considered a valuable material to fabricate external lenses to correct refractive 
deficiencies of eyes. Furthermore, the use of some special glasses and glass-ceramics, that are 
defined “bioactive” due to the their unique capability of stimulating cell activity and tissue 
regeneration in vivo, could disclose new, fascinating scenarios in ocular surgery. 
In biomaterials science, the word “bioactive” generally means that the material stimulates an 
advantageous biological response from the body on implantation. The term was coined by Larry 
Hench in the early 1970s, when he and his colleagues at the University of Florida invented 45S5 
Bioglass®, the first material able to form a strong bond to bone.1,2 This discovery launched the field 
of bioactive glasses (BGs) and glass-ceramics (BGCs) and, even most importantly, introduced the 
basic concept of modern regenerative medicine, i.e. some special materials not only are not rejected 
by living tissues but can elicit a therapeutic action in the human body. Initially, bioactivity referred 
to materials that could bond to bone (osteoconduction), but 45S5 Bioglass® was later found to 
stimulate new bone growth (osteoinduction) and to bond to soft tissues.3  
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The applications of BGs and BGCs in the medical field have been mainly related to the repair of 
hard tissues, like bone and teeth, and over the years tens of compositions have been investigated and 
clinically tested in orthopaedics and dentistry.4-9 The use of BGs and BGCs in ocular surgery might 
seem an unusual and marginal application, since the eye comprises a variety of soft, delicate 
structures that, apparently, are mechanically unmatchable with stiff and brittle BGs; in this regard, 
polymeric substances, in form of injectable gels or flexible products, would seem much more 
suitable and effective.10-14 Reviewing the available literature, however, we found that BGs and 
BGCs have been applied with promising outcomes in three sub-areas of ophthalmology: (i) 
oculoplastic surgery for the repair of eye orbit floor, (ii) orbital implants for anophthalmic surgery 
and (iii) artificial cornea.  
Facial trauma to the midface can lead to fractures in the inferior/medial orbit wall15 with herniation 
of the orbital contents into the maxillary sinus located underneath (Fig. 1). Surgical intervention is 
necessary to treat this type of injury: the implant aims to act as a bone graft ensuring structural 
support at the bone defect site (fracture) and is often designed as a porous scaffold to promote bone 
in-growth and a safe anchorage to surrounding host tissues.16 Autologous bone graft is usually the 
preferred option to repair the defect, although it carries the need for extra-surgery at the harvesting 
site. Porous hydroxyapatite (HA) and polyethylene (PE) implants are also used, but problems of 
brittleness occur with the former during implantation and the latter does not induce new bone in-
growth.16  
Porous HA, PE and alumina are also the most commonly-used materials for producing orbital 
implants (Fig. 2) to be placed in the patient’s anophthalmic socket after evisceration or enucleation 
due to trauma or otherwise untreatable diseases (e.g. tumours especially in infancy).17 The presence 
of an interconnected macroporous network in these materials is crucial to obtain an adequate 
postoperative fibrovascularization of the porous orbital implant, which is a desirable characteristic 
in view of exposure-related infections as vascular in-growth helps to anchor the implant, permits 
immune surveillance and makes possible the treatment via systemic antibiotics. 
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As to the third application it is impressive to mention that, according to the World Health 
Organization,18 corneal diseases (e.g. age-related degeneration, infections, 
chemical/thermal/mechanical injuries) are the 4th largest cause of blindness worldwide. Although 
corneal transplantation is the most common treatment of corneal blindness, the limitation in the 
storage of corneal tissue as well as cultural or religious barriers remain a problem; furthermore, 
failure of the transplanted graft is not uncommon.19 An interesting alternative is the implantation of 
a keratoprosthesis (artificial cornea), generally comprising a transparent optical core supported by a 
skirt that anchors the implant within the host corneal tissue. Many types of keratoprostheses have 
been developed and are currently used in the clinical practice; most of them are fully constituted by 
polymeric materials, like the so-called “Boston keratoprosthesis” entirely made of 
poly(methylmetacrylate) (PMMA) or other models comprising an optical element made of PMMA 
or transparent hydrogel supported by a porous polymeric skirt.19 With the aim to enhance the bond 
between keratoprosthesis and surrounding tissues through the promotion of better cell adhesion, 
Strampelli pioneered the use of the osteo-odonto-keratoprosthesis (OOKP) (Fig. 3), wherein a 
lamina prepared from a single-root tooth extracted from the patient is used to form a biocompatible 
skirt around the PMMA core.20 A relatively good, long-term clinical outcome can be achieved with 
the OOKP also in dramatic cases (e.g. patients with dry eye or Stevens-Johnson syndrome1); 
however, the complexity of OOKP surgery and the need for sacrificing the autologous tissues make 
this approach stressful for patients. Furthermore, local inflammation can decrease the pH of the 
tissue, thereby causing the degradation of the tooth-derived prosthetic skirt, device instability and 
final loss of the OOKP.21  
The use of BGs and BGCs in all these three contexts of application could contribute to overcome 
some shortcomings related to the existing devices, thus opening new research directions. After 
                                                          
1
 Stevens-Johnson syndrome (SJS) is a form of life-threatening skin condition, in which cell death causes the epidermis 
to separate from the dermis. This syndrome is thought to arise from a disorder of the immune system, leading to a 
hypersensitivity complex that affects the skin and the mucous membranes. The immune reaction can be triggered by 
drugs administered to treat other pathologies (in most cases), infections or, more rarely, cancer. Outcomes of SJS 
include serious organ damage as well as corneal disease which may eventually cause blindness. 
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giving the reader an overview about the use of glass in ocular surgery, this article focuses on the 
ocular applications of BGs and BGCs and highlights the challenges and promises for the future, 
especially in the light of the recent findings in tissue engineering. Finally, some methodological 
remarks about the need to elaborate standard guidelines for selecting and testing potentially 
implantable BGs and BGCs for ophthalmic use are presented at the end of the work. 
 
TRADITIONAL GLASS-BASED IMPLANTS IN OCULAR SURGERY: A HISTORICAL 
OVERVIEW 
 
Glass has been employed for making external corrective lenses since the Roman Age (e.g. the 
famous philosopher Seneca reports the use of glass spheres to magnify objects in the 1st century 
AD), but its use as an implantable material in ophthalmology is more recent, dating back to the mid 
1700s. The first evidence was reported in the book “The Memoirs of Casanova”, where the great 
lover described a meeting with an Italian itinerant ophthalmologist, Tadini, at a dinner in Warsaw in 
1765.22 Tadini showed him some polished glass spheres in a box and claimed that he could implant 
them underneath the cornea to replace the crystalline lens. A fellow guest, an unnamed German 
ophthalmologist, ridiculed the claim in print and Tadini never mentioned the spheres again, but 
Casanova may have been responsible for conveying the idea to the Court at Dresden where, few 
years later, the ophthalmologist Casaamata unsuccessfully tried to insert a glass lens underneath a 
corneal wound.22 This is recognized as the first (failed) attempt to correct aphakia via implantation 
of a glass intraocular lens (IOL). Only almost two centuries later, in 1950, Sir Harold Ridley 
successfully performed the first implantation of a IOL during cataract surgery using a lens of 
PMMA, that is the material commonly used till now; glass is considered unsuitable for this 
application due to its too high density.23 
Glass was also the first material employed to make a keratoprosthetic device. Pellier de Quengsy is 
traditionally considered as the first who proposed an artificial cornea in his comprehensive treatise 
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of ocular surgery published in 1789:24 he suggested the use of a thin silver-rimmed convex glass 
disc as a keratoprosthesis and described in great detail the surgical instruments suitable for its 
insertion. According to the studies by Chirila and Hicks,25 Pellier de Quengsy was also the first to 
suggest a porous periphery (skirt) for the keratoprosthesis, thus anticipating an important strategy 
for the prosthesis anchorage which will be developed only several years later. However, there is no 
proof that an actual implantation of this device was ever performed and only 60 years later Von 
Nussbaum implanted in rabbits and human patients a glass keratoprosthesis.26 Since then, the use of 
glass to manufacture the optical core of keratoprostheses was accompanied by controversial results 
and, after the Second World War (WWII), it was commonly substituted by the lighter PMMA. In 
recent years, the unique exception has been represented by the “champagne cork” keratoprosthesis, 
developed by Worst and co-workers in the 1980s.27 This model had a shape similar to a mushroom 
and consisted of a glass core mounted in a platinum cylinder provided with a flange, through which 
four stainless steel wires were passed for the fixation to the sclera.28 This keratoprosthesis was 
initially implanted in a large number of cases in India from the 1980s to the early 1990s with a high 
rate of success.29 However, as pointed out by Chirila et al.,30 these apparently good outcomes are 
questionable as they refer only to the immediate postoperative follow-up and most of patients never 
came back for subsequent, long-term examination. This prosthesis has been still used more recently 
because it provides a significantly wider range of vision in comparison to other models,31 but it 
suffers from late problems with the tension on the stainless steel sutures that causes them to erode 
through the tissues, thus leading to instability of the implant and damage to the eye. 
Apart from being used to correct visual deficiencies, glass was also employed for aesthetic purposes 
in the fabrication of artificial eyes. In this regard, the first evidences of the so-called “glass eyes” 
date back to the end of 18th century, when Venetian glassmakers, taking inspiration from dolls’ 
eyes, began to produce prosthetic human eyes in the form of thin, highly brittle glass shells.32 In 
1885 Mules first described in detail the surgical placement of a hollow glass sphere into an 
eviscerated globe.33 Since the early 1900s, glass ocular prostheses began to be coupled with an 
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orbital implant in order to restore a better aesthetic appearance to the patient’s face; the prosthesis 
was a glass shell placed between the closed conjunctival surface covering the orbital implant 
(bulbar conjunctiva) and the eyelids (palpebral conjunctiva) (as shown in Fig. 2). Glass eyes had to 
be worn with caution as they were brittle and prone to implosion with acute changes in temperature; 
furthermore, they became etched from exposure to body secretions. Glass remained the standard 
material for making ocular prostheses and orbital implants (hollow sphere) until WWII, when they 
were progressively replaced by PMMA devices34 that definitely overcame the problems of 
brittleness, permitted custom fitting at a relatively low cost and allowed better motility of the 
prosthesis. In the last decades, the use of glass spheres as orbital implants has been almost totally 
abandoned; occasionally, however, glass has been still employed in selected cases. In the late 1980s 
Helms et al.35 implanted a glass sphere in 1 patient and unfortunately the device underwent 
posterior intracranial migration. One decade later Christmas et al.36 used a glass implant in a single 
patient without reporting any complication after a 2-year follow-up. 
 
CURRENT APPLICATIONS OF BGs AND BGCs IN OPHTHALMOLOGY 
 
In all the “traditional” applications presented in the previous section glass has been employed as an 
optical or aesthetic element of implantable ocular devices; on the contrary, the concept behind the 
use of BGs and BGCs lies on a completely different approach. Essentially, the experimentation of 
BGs and BGCs as eye orbit floor grafts, orbital implants and keratoprosthetic skirts was proposed in 
the attempt to improve implant biointegration, which is tightly related to the postoperative success 
of the implanted device. 
Table I collects the currently-available clinical or experimental studies dealing with the use of BGs 
and BGCs in ocular surgery; the specific applications and essential characteristics of the related 
devices are also summarized for the reader’s benefit. These studies are reviewed and critically 
discussed in the following three subsections, depending on the context of application. 
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Eye orbit floor repair 
 
To date, the use of BGs for orbital floor repair is limited to a series of studies performed from the 
late 1980s to the early 2000s on four series of human patients by two teams of Finnish researchers. 
In all those studies, the aim was to investigate the suitability of curved plates obtained from cast 
S53P4 silicate glass (oxide weight composition: 53% SiO2, 23% Na2O, 20% CaO, 4% P2O5) as 
synthetic grafts to repair orbital fractures.  
Suominen and Kinnunen,37 affiliated to the Helsinki University Central Hospital, first implanted 
S53P4 granules and plates at 36 sites in 13 patients, comparing the behaviour of this material with 
that of bone grafts at 16 sites in the same patients. BG granules were used in facial bone defects in 
subperiosteal pockets and to obliterate frontal sinuses, whereas the plates were employed for orbital 
wall reconstruction. Clinical examination, middle face radiographs and computed tomography (CT) 
scanning showed that the BG was generally well tolerated. The glass plates retained their density, 
did not change in size and were characterized by tighter contact with the host bone in comparison to 
BG granules and bone grafts. The clinical outcome showed no relapses after a 1-year follow-up and 
no further operations were needed to remove or adjust the implanted material. 
On the basis of these promising results, the studies were continued by another research group at the 
Turku University Hospital. Kinnunen et al.38 compared the use of melt-derived S53P4 glass plates 
with conventional cartilage grafts for the treatment of traumatic orbital floor fractures in 28 patients 
operated from 1991 to 1995 and evenly split in two groups of 14 people. None of 14 patients 
receiving the S53P4 plate showed significant evidence of implant-related postoperative 
complications; in addition, their clinical outcomes (only 1 case of infraorbital nerve paraesthesia 
and 1 case of entropion2 were registered) were better than those the cartilage group (3 cases of 
                                                          
2
 Folding inwards of the eyelid (usually the lower eyelid), which causes the eyelashes to constantly rub against the 
cornea. 
Bioactive glasses in ocular surgery 
 
9 
 
diplopia, 2 case of infraorbital nerve paraesthesia and 1 case of enophthalmos3). The authors of this 
study concluded that the use of BGs plates led to less morbidity as no donor site operation is needed 
and S53P4 glass provided favourable healing due to its ability to stimulate new bone formation, 
which encouraged further investigations. Aitasalo et al.39 reported a retrospective study of 36 
patients operated from 1995 to 1999: after a 1-year follow-up, the S53P4 glass implants caused no 
foreign body reaction in the bone or soft tissue as well as no infection, haemorrhage and implant 
displacement/extrusion4; CT scanning qualitatively demonstrated new bone growth around the 
implanted BG plates. Peltola et al.40 reviewed the postoperative outcomes of 49 patients receiving a 
S53P4 glass plate from 1998 to 2001 (Fig. 4). These authors developed a set of stainless steel 
templates to guide the selection of the correct glass plate so that it almost perfectly fitted the 
surrounding orbit bone defect margins and anatomy. No signs of implant-related infection, 
extrusion or displacement were observed over a 2-year postoperative follow-up; furthermore, the 
implants caused no foreign body reaction, new bone formation was observed around the glass plates 
and only a minor resorption was found on the margins of the implants. Part of these results was also 
presented in the form of a conference abstract by Aitasalo et al.41 
From the data reported in this series of studies, BG plates appear a promising and reliable solution 
for orbital floor reconstruction; specifically, S53P4 glass is biocompatible, bioactive (i.e. able to 
stimulate new bone growth) and slowly biodegradable (thereby ensuring adequate structural support 
while bone regenerates); furthermore, if the glass implant size and shape are properly selected, 
excellent functional and aesthetic results can be achieved.  
 
Orbital implants 
 
                                                          
3
 Recession of the ocular globe or orbital implant within the orbit; it may be acquired as a result of trauma (e.g. blow-
out fracture of the orbit) or related to postoperative complications of oculo-orbital surgery. 
4
 “Extrusion” is the commonly used surgical term to describe the expulsion or spontaneous removal of an ocular implant 
from the host tissue, without any connotation of its meaning in polymer technology. 
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Silicate BG and BGC formulations have been also proposed for the manufacture of porous orbital 
implants in the form of single-phase materials or as a second phase added to a polymeric matrix 
(composites). There is a general paucity of scientific literature on this topic; most of available 
studies were performed by four groups of Chinese researchers.  
In the late 1990s, Xu and co-workers42 implanted BGC porous orbital implants in enucleated rabbits 
and observed no rejection during a 6-month postoperative follow-up; ultrasound examination 
revealed a venous-flow-like spectra in the implants after 3 months and histological analysis showed 
that around 90% of the implant pores were filled by fibrovascular tissue after 6 months from 
operation. Encouraged by these promising results, the same authors implanted the BGC orbital 
implants in 102 human patients, declaring a success rate of 96.1% (98 cases).43 In 4 cases the 
conjunctiva was torn partly when suture stitches were taken out of the wound, and the orbital 
implant removal was necessary in 1 patient. There were no reported complications after a follow-up 
of 6 months to 2 years and all patients were satisfied with their cosmetic appearance, although 
implant drilling and placement of the motility peg to connect the implant to the ocular prosthesis 
were not performed as a secondary procedure. 
After a time gap of 10 years, BG was recently experimented to fabricate PE-based composite 
porous implants. In 2006, Choi et al.44 analyzed the effect of BG particulate on the fibrovascular in-
growth occurring in porous PE-based orbital implants in rabbits. Forty-eight rabbits were divided 
into 4 equally-sized groups, according to the different surgical techniques and implanted materials 
employed: groups 1 and 2 received a porous PE sphere after enucleation or evisceration, 
respectively (reference groups), whereas groups 3 and 4 received a porous BG/PE composite 
implants after enucleation or evisceration, respectively. Histological examinations revealed that 
there was no statistically significant difference with regard to fibrovascular in-growth among the 4 
groups after a 8-week postoperative follow-up. Therefore, in this preliminary study the authors 
concluded that inclusion of BG particulate did not significantly promote the rate of fibrovascular in-
growth into porous PE-based orbital implants. In 2011, Ma et al.45 reviewed the clinical outcomes 
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of 170 human patients after placement of porous BG/PE composite orbital implants for primary 
enucleation or secondary implantation. The majority of patients (161 cases) experienced no 
complications, the implant motility was generally good and no cases of implant-related conjunctival 
thinning or inflammation were observed. Excessive discharge and implant postoperative exposure 
occurred in 2 and 7 cases, respectively; additional surgery was necessary in 8 patients. These results 
suggest that the porous glass/PE composite orbital implant may be a useful alternative to other 
existing options, although its real advantages are currently unclear. Comparative studies are still 
necessary to definitely estimate their performance with respect to the commonly available and 
routinely used implants.  
It is interesting to mention a very recent study by Ye et al.,46 who coated porous HA orbital 
implants with a sol-gel derived CuO-containing mesoporous BG (Cu-MBG) (Fig. 5). The aim was 
to combine the antibacterial effect (copper shows potent antibacterial activity in suppressing a range 
of bacterial pathogens involved in hospital-acquired infections47) and drug delivery capacity (drug 
molecules can be hosted within the mesopores48) of the Cu-MBG coating to improve the final 
outcomes of anophthalmic socket surgery. Cu-MBG coatings with 0-5 mol.% of CuO were directly 
prepared in the pore walls of porous HA implants by dipping in the sol precursor of the glass, 
followed by evaporation and ageing. With the peculiarity of releasing antibacterial ions as the Cu-
MBG degrades (viability of Staphylococcus Aureus (S. Aureus) and Escherichia Coli (E. Coli) was 
inhibited) and good drug uptake/delivery ability (in this study ofloxacin), Cu-MBG-coated porous 
HA orbital implants are promising in the prevention of implant-related infections. Moreover, there 
is an additional, perhaps even more important reason why the approach pioneered by these authors 
is so fascinating: it was demonstrated that Cu2+ induces migration and proliferation of endothelial 
cells during in vitro culture, which could lead to an improved fibrovascularization of the orbital 
implant in vivo. Looking at the future, appropriate design of BG composition could impart 
angiogenetic properties to the material for enhancing the fibrovascular in-growth, which would 
actually represent a key added value for orbital implants. 
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The use of BGs to fabricate orbital implants was also claimed in a recent patent by Richter et al.49 
but, to the best of the author’s knowledge, no manufacturing or clinical studies have been reported 
yet in the literature on this type of implant. 
Another interesting application was reported by Heringer and Ng,50 who proposed the use of BG as 
a “contingency plan” to fill old peg tracts and to permit re-pegging in porous HA orbital implants, if 
the initial drilled tunnel was not perpendicular and central to the implant surface. These authors 
removed the implant pegs and/or sleeves of 3 patients who had pegged HA orbital implants with 
related complications and, over a 2-year period, did not respond to conservative treatment. Peg 
tracts were subsequently filled with BG and no subsequent complications occurred in any case 
during 3 years of follow-up. After 2 months, 2 patients underwent successful re-drilling of the peg 
site with insertion of titanium pegs with good outcomes (the third patient deferred re-pegging at that 
time) and satisfactory connection to the ocular prosthesis. 
 
Keratoprostheses 
 
Glass has been traditionally used to fabricate the optical core of keratoprostheses (especially in the 
early models) due to its transparency to visible light. On the contrary, the concept behind the use of 
BGs and BGCs is completely different: over the last 35 years, some of these special glasses have 
been employed in the manufacturing of keratoprosthetic skirts with the final aim of improving 
biointegration. As pointed out by Chirila,51 the skirt material should preferably be hydrophilic in 
order to encourage the penetration of biological fluids from the host tissue, as an initial step in the 
biocolonization of the porous skirt. In principle, this requirement could be successfully fulfilled by 
BGs and BGCs, that are able to expose hydroxyl groups after contact with aqueous solutions and 
are characterized by a good water wettability. In the late 1970s, some BGC formulations belonging 
to the group called “Ceravital” were proposed to fabricate an anchorage skirt around experimental 
OOKP;52-55 however, the tendency of these materials to progressively dissolve after contact with 
Bioactive glasses in ocular surgery 
 
13 
 
biological fluids caused concerns about their suitability in vivo due to the consequent loss of their 
supporting function and, therefore, the investigations were discontinued. After a time gap of 15 
years, Krause reported a concise study about the intracorneal biocompatibility of Bioverit® I and II 
in rabbit eyes:56 the materials were incorporated into the host corneal tissue almost without irritation 
and no toxic or immune reactions were observed. Few years later, Linnola et al.57 investigated the 
suitability of an apatite/wollastonite (A/W) glass-ceramic coating to solve a specific problem related 
to keratoprostheses, i.e. the in-growth of corneal or conjunctival epithelium into the anterior 
chamber, which may lead to infections and extrusion of the implant as well as to the development of 
retroprosthetic membrane and secondary glaucoma. The concept behind this study was that a 
material able to fasten the prosthesis to the corneal tissue before the epithelium grows inward could 
prevent these complications. The experimented keratoprostheses had a PMMA optical core 
supported by a titanium flange coated or not with a A/W glass-ceramic layer; 11 keratoprostheses 
for each of the two series were implanted in rabbit corneas. Histological analysis showed no 
significant in-growth of epithelium in 83% and 73% of the analysed areas of the A/W glass-ceramic 
coated and bare titanium prostheses, respectively; therefore, the authors of this study concluded that 
the use of a BGC coating was an effective strategy to hinder the corneal epithelium in-growth.  
After another time gap of 15 years, some very interesting studies have been published by different 
research groups. Santos et al.58 investigated the properties of a glass-reinforced HA (GRHA) porous 
composite for potential use as a new synthetic material for the skirt of artificial cornea (Fig. 6(a)). 
This study is valuable also from a methodological viewpoint as the authors justified the suitability 
of the prepared material according to a defined protocol that included evaluation of pores 
characteristics, degradation in biological media at different pH (following the relevant ISO 
standard59) and in vitro cell viability (human dermal fibroblasts were used). GRHA was obtained 
through the addition of 2.5 wt.% of a phosphate glass (molar composition: 65P2O5–15CaO–
10CaF2–10Na2O) to HA powder prepared by chemical precipitation. Poly(vinyl alcohol) was added 
as a porogen agent (10-50 vol.%) to the powder mix, that was pressed and finally sintered at 1300 
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°C for 1 h to obtain small porous disks. Degradation studies showed that no mass loss was found 
under simulated physiologic conditions (immersion in Tris solution); on the contrary, a significant 
mass loss was observed under acidic conditions (immersion in citric acid solution). The biological 
performance of these samples was satisfactory when cultured with human fibroblasts, that invaded 
the material porous network, grew and proliferate over a 14-day culture period. The mean pore size 
of 110 µm was found adequate to allow implant colonization by cells.  
In the search for a suitable synthetic substitute of the dental laminate of OOKP, Laattala et al.60 
proposed a PMMA-based composite in which BG particles (40 wt.%) were added to the polymer 
matrix; four different glass compositions, including 45S5 Bioglass®, S53P4 and two other 
experimental formulations, were tested. These authors tried to solve the problems of the loosening 
of the optical cylinder in the Strampelli’s OOKP due to the reabsorption of the autologous skirt. 
PMMA was chosen as a potentially suitable material to firmly anchor the keratoprosthesis, but it 
was too inert to be used on its own; therefore, a BG phase was added to enhance the bioactivity of 
the device, intended in this case as the ability to promote corneal cells adhesion. The dissolution 
behaviour of the composites in simulated aqueous humour, as well as the changes in the 
compressive strength and Young’s modulus after soaking for 6 weeks in this testing solution, were 
investigated. A decrease of the mechanical properties after soaking in simulated aqueous humour 
was observed due to BG particles dissolution with an associated porosity increase; this behaviour 
was partially suppressed by the formation of apatite on the BG particle surface. In general, it should 
be taken into account that the progressive BG dissolution and the weak interfaces between BG 
particles and PMMA matrix (due to the lack of a covalent bond) permitted the penetration of water 
molecules into the composite, which could eventually lead to local disintegration; this issue 
deserves careful investigation as the maintenance of the device integrity in vivo is a key goal to be 
achieved. Another drawback related to the use of these composites is that the actual exposure on 
surface of BG particles, and hence their actual efficacy, was not known since the BG particles were 
dispersed within the polymeric matrix. Furthermore, the authors observed the presence of a thin 
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PMMA skin layer that covered the BG particles after the manufacturing of the composite; this 
polymeric layer could be eliminated from the outermost surface by grinding or manipulating with 
an organic solvent. Promising prototypes were obtained demonstrating the feasibility of the 
proposed approach (Fig. 6(b),(c)), but in vitro tests with cells (e.g. keratocytes) will be necessary to 
assess the actual suitability of the composite skirt for clinical use.  
In 2013, Huhtinen et al.61 investigated two experimental silico-boro-phosphate BGs of different 
compositions (1-98: 5.9Na2O-7.1K2O-7.6MgO-23.9CaO-0.9B2O3-0.9P2O5-53.8SiO2; 28-04: 
4.9Na2O-7.2K2O-9.0MgO-16.2CaO-2.6B2O3-60.1SiO2, mol.%) as potential substitutes of the tooth-
derived skirt of the OOKP. The glasses were produced by melting-quenching route, crushed and 
sieved into the 250-315 and 315-500 µm size ranges to assess the influence of different dimensional 
ranges besides that associated to composition; the particles were then sintered in a graphite mould 
into ring-shaped structures with interconnected porosity. In vitro tests with keratocytes showed that 
none of the porous BG structures induced a cytokine driven inflammatory response and the adherent 
keratocytes exhibited a typical elongated, spindle-shaped morphology which suggested a good 
adhesive potential. These preliminary investigations support the use of porous BG as a synthetic 
OOKP skirt, even if dissolution of the glass over time may destabilise the OOKP, indicating that a 
composite system with a stable backbone structure would be necessary to maintain the optical core 
in the correct position while the BG chemically dissolves; in this regard, the study by Laatala et al.60 
(previously presented) can provide useful research inputs. Future studies in an animal model would 
be necessary to explore the systemic effects of the dissolution products from these BGs as well as 
the impact of ion release and pH change in the eye.  
An interesting in vivo investigation was reported by Liang et al.,62 who implanted experimental 
BGC disks (diameter 8 mm, thickness 0.5 mm, pore diameter 20-70 µm, porosity 37-62 vol.%) in 
11 albino rabbit corneas. The implants with higher porosity (51-62 vol.%) were all extruded due to 
breakage (5 cases); the other major complications included corneal oedema with severe degrees of 
corneal neovascularization within 1 month postoperatively, opacity of the corneal lamella after 2 
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months and lipid deposits (4 cases). Furthermore, the implant was too hard to be cut, thus making 
difficult the histological examination. Therefore, the authors of this study judged the chosen BGC 
unsuitable as peripheral keratoprosthetic materials because of excessive roughness, hardness, 
thickness and tendency to breakage; perhaps, an optimization of the structural design parameters 
(e.g. implant thickness, pore size and interconnectivity) maintaining unaltered the material 
formulation may lead to more satisfactory results. 
 
TOWARDS TARGETED THERAPEUTIC APPLICATIONS AND EYE TISSUE 
ENGINEERING USING BGs AND BGCs: PROMISES, CHALLENGES AND CRUCIAL 
ISSUES 
 
Possible advances provided by the use of BGs and BGCs in ocular surgery over the existing state-
of-the-art solutions are briefly summarized in Table II; these concepts will be discussed in the 
details in the following paragraphs. 
With respect to the currently-employed biomaterials for ocular surgery (e.g. HA, PE, alumina), the 
most fascinating added value of BGs and BGCs is the unique ability to release appropriate ions with 
the aim of inducing a specific, desired response in vivo. It has been demonstrated that ionic 
dissolution products play a key role in affecting the biological response of biomedical materials in 
vitro and in vivo, stimulating cell activity or exerting other appropriate functions (e.g. antibacterial 
effect); in this regard, BGs have received great attention by researchers due to their adjustable 
reactivity in the biological environment.63,64 Since many trace elements present in the human body 
are known for their anabolic effects in cells metabolism, a new approach for designing BG-derived 
products able to elicit a specific biological response for targeted applications could be based on the 
introduction of therapeutic ions into the BG formulation. The subsequent release of these ions after 
exposure to a physiological environment can exhibit osteogenetic,63 antibacterial,65 anti-
inflammatory66 or angiogenetic effects.67-72 This fascinating scenario was impressively called 
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“genetic design of bioactive glass” by Prof. Hench, the inventor of 45S5 Bioglass® who entitled in 
this way one of his publications.63 In the specific context of ocular surgery, the ability to bond to 
bone stimulating new bone formation is a key property for orbital floor implants; antibacterial 
action would be generally very useful for all ocular implants; finally, BGs able to promote 
angiogenesis can open interesting perspectives in the field of porous orbital implants, whose 
fibrovascularization is a crucial requirement to maintain the implant in place and to reduce the risk 
of exposure-related infections. In vitro experiments have shown that BGs stimulate the secretion of 
angiogenic growth factors in fibroblasts, the proliferation of endothelial cells and the formation of 
endothelial tubules;67,69 early in vivo results assessed the neovascularization of porous BG 
implanted in rats.69-71  
BG and BGC compositions can be properly designed to obtain materials with different degrees of 
solubility by varying the ratios between the constituent oxides (e.g. SiO2, P2O5, Na2O and CaO) 
and/or incorporating additional metal oxides; in this regard, biocompatible phosphate glasses can 
offer a wide range of dissolution kinetics.73 It has been demonstrated that metal oxides such as 
TiO2, CuO, AgO and Fe2O3, apart from modulating the phosphate glass solubility, are also useful in 
exerting an antibacterial effect via the release of the relevant metal ions. In this regard, the recent – 
and currently unique – study by Ye at al.46 about the antibacterial effect of Cu2+ released from 
MBG-coated HA porous orbital implants opens interesting perspectives for the development of 
novel ocular devices with antiseptic functionalities.   
The use of soluble materials as ocular implants, however, deserves careful attention depending on 
the context of use. Potentially suitable BGs and BGCs for orbital floor repair are expected to exhibit 
an adequate surface reactivity to promote the bond to the host bone via the series of ion-exchange 
reactions described by Hench et al.;1 as a general rule, the implant solubility must be compatible 
with bone healing rate. In this regard, the solubility of S53P4 glass orbital plates, that are currently 
the unique BG implants clinically employed for this purpose, is quite moderate.37-41 On the 
contrary, orbital implants should be conceived as permanent devices, i.e. they must remain in situ 
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indefinitely during the patient’s whole life without undergoing degradation to ensure an adequate 
socket volume replacement. An interesting exception was disclosed in a patent deposited in the late 
1990s by Durette,74 who proposed an orbital implant preferably made of biodegradable material 
(including glass) and having a matrix with random voids throughout to enhance tissue in-growth. 
The use of a partially absorbable orbital implant able to increase its porosity in vivo, thereby 
allowing an improved fibrovascularization postoperatively, represents a fascinating concept; 
however, this approach poses several problems which should be carefully and critically examined, 
especially concerning the kinetics of socket volume replacement by tissue while the implant resorbs 
and the ocular prosthesis motility in the partial or total absence of an orbital implant that can 
transfer movement to it. In the field of artificial cornea, resorption of the porous skirt around the 
optical core is an unwanted effect that would lead to the loosening of the keratoprosthesis;21 this 
problem was the major reason why synthetic alternatives to the tooth-derived skirt of Strampelli’s 
OOKP have been proposed, including BG-based materials.58,60,61 Therefore, the use of BGs and 
BGCs able to maintain adequate integrity over time in vivo is recommended for this specific 
application. On the other hand, it cannot be ignored that chemical and biological stability competes 
with the capability of BGs to release therapeutic ions via controlled dissolution. This specific 
problem is only one of the aspects of a wider issue concerning the surgical applications of BGs and 
BGCs, that are excellent biomaterials to be replaced or invaded (if porous) by regenerating tissues 
but, if used as connecting or joining elements between various prosthetic permanent components (as 
in the case of synthetic OOKP), they must ensure indefinite and safe stability and should not 
dissolve in biological fluids. 
BGs and BGCs are attractive also from a technological viewpoint due to the relative ease of 
processing associated to their production. BGs can be employed in the form of powder to produce 
3-D porous scaffolds with different size, shapes, pore architecture and mechanical properties 
through a number of relatively easy, inexpensive methods like sponge replica technique,75,76 sol-gel 
foaming77 and polymeric particles burning-out.78 Rapid prototyping techniques, such as selective 
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laser sintering79 and robocasting,80 can allow custom-made porous BG implants to be fabricated. A 
clever approach could involve the use of microCT- or MRI-derived files as input data for 
CAD/CAM manufacturing systems in order to produce scaffolds exactly matching the required 
anatomical dimensions. This strategy was already successfully applied for the production of HA 
porous implants for oculoplastic surgery.81-83 In this way, the size of porous plates for orbital floor 
repair could reproduce the contour of the bone fracture, the orbital implant volume could be 
properly adapted to fit the individual eye socket, and the porous skirt of synthetic OOKP could be 
tailored according to the features of each patient’s eye. 
BGs can be also produced in form of mesoporous materials (MBGs, with an ordered pore 
arrangement with pore size within 2-50 nm)84 that, hosting anti-inflammatory drugs or antibiotics, 
could impart a significant added value to implantable ocular devices since intra- or postoperative 
infections are one of the major causes of failure of ophthalmic implants. Before implantation, 
porous ocular biomaterials are usually soaked by the ophthalmic surgeons into an antibiotic 
solution; however, this common practice is quite rough and the antibiotic is released as a burst after 
contact with biological fluids in situ. Drug release from MBGs would allow a prolonged therapy to 
be performed, with a higher control on the amount of incorporated drug and the release kinetics, 
which both can be pre-determined as a function of the mesopores shape and size. A serious 
drawback of MBG constructs is the high brittleness due to the presence of an intrinsic mesoporous 
texture (compressive strength within 50-250 kPa85), which poses serious problems for material 
shaping at the time of surgery and safe implantation without loss of integrity. High solubility of 
MBGs related to the high surface exposed to biological fluids is another issue to be taken into 
account. The use of MBGs as coatings on a mechanically and chemically stable porous backbone, 
as proposed by Ye et al.,46 could be an effective solution to these shortcomings. 
Looking at the future, the use of BGs and BGCs in ophthalmology could also disclose new 
therapeutic approaches for the treatment of ocular tumours. Tumours affecting the orbital bone or 
ocular tissues are one of the main non-traumatic causes requiring the surgical resection of the 
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orbital bone or the removal of the ocular globe. The surgical procedure typically comprises two 
stages: (i) removal of the diseased tissue (orbital bone portions and/or the ocular globe) and (ii) 
implantation of an appropriate biomaterial or device (orbital bone graft and/or orbital implant 
replacing the socket volume). Therefore, the clinical challenge is twofold: it is necessary not only to 
successfully restore the surgically-induced defect, but also to avoid the re-development of the 
tumour. In this regard, hyperthermia using implantable magnetic BGs and BGCs has emerged as a 
promising option for the localized treatment of malignant tumours.86 At present, the researches and 
clinical applications of hyperthermia mediated by magnetic materials are mainly addressed to the 
treatment of bone tumours; the suitability of this approach to treat orbital bone/intra-orbital 
malignancies would deserve consideration in the next future. In this regard, for the sake of 
discussion it is instructive to mention a recent work by Wu et al.,87 who proposed an innovative 
approach combining hyperthermia therapy and local drug delivery in a multifunctional Fe-
containing hierarchical porous MBG scaffold prepared through a co-templating method. Large 
macropores are useful to permit healthy tissue in-growth, mesopores allow sustained drug release 
and the magnetic properties of the Fe-containing glass can be exploited for in situ cancer treatment 
by hyperthermia. As mentioned above, high brittleness of MBG constructs is a serious shortcoming 
that limits the clinical applications; perhaps, injectable magnetic MBG pastes could be suitable for 
the repair of cancer-derived orbital bone defects or be introduced intraorbitally in the region around 
the severed optic nerve to kill the residual cancer cells that might migrate through it after 
enucleation. MBGs hosting and releasing antineoplastic drugs could be also considered for the 
treatment of orbital bone tumours or intra-orbital malignancies, like retinoblastoma, which is the 
major cause of enucleation in children.  
Use of radioactive BGs, initially proposed by Day and Day88 for the treatment of liver cancer, 
deserves to be mentioned in this review as a possible stimulus for future research, in the attempt at 
developing less invasive approaches to treat ocular tumours, decreasing the radiation dosage 
required to kill the cancer cells and minimizing the overall side effect toxicities. In current 
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applications, 89Y-containing glasses in the Y2O3-Al2O3-SiO2 ternary system were produced in the 
form of 20 to 30 µm microspheres (TheraSphere®); before arterial infusion, the glass beads were 
bombarded by neutrons that create 90Y, a radioisotope that is a short-half-life (64 h), short-range β-
rays emitter. In this way, a localized dosage of up to 15000 rad was delivered, whereas a maximum 
of 3000 rad under external radiation can be tolerated by the patient. The selected ternary glass 
system provided excellent chemical durability in the body in order to avoid dissolution and 
migration of the radioisotope via the blood circulation; at present, radioactive glass microspheres 
are clinically used as an adjuvant to liver surgery at a number of clinical centres in USA, Canada 
and EU countries after receiving FDA approval in 1999. 
A very versatile way to impart special properties to BGs and BGCs involves surface modifications. 
It has been demonstrated that in aqueous environment silicate BGs and BGCs can expose reactive 
hydroxyls groups on their surface, that can be employed for the grafting of appropriate 
biomolecules to improve bioactivity or elicit specific therapeutic actions.89 In this context, 
functionalization of MBG pore walls has been successfully experimented.86 Looking at possible 
ophthalmic applications, the idea of grafting specific growth factors, like the vascular endothelial 
growth factor (VEGF) to enhance vascularization, or drugs to reduce inflammation and infection, 
could be of high interest in the field of orbital implants. Another strategy to impart added values to 
biomaterials is the deposition of a coating on the implant surface. Since implant-related ocular 
infections are responsible for serious postoperative problems requiring expensive and stressful 
extra-treatments for the patients,90-93 a smart coating able to elicit an antibacterial/antifungal effect 
would be of great importance for ophthalmic biomaterials. In this regard, Baino et al.94 disclosed in 
a recent patent the application of an antibacterial oxide-based composite film on the surface of 
orbital implants and ocular prostheses. The coating, whose thickness can be modulated from 10 nm 
to 1 µm, is produced by radio-frequency co-sputtering of silver and silica and is constituted by 
silver nanoclusters embedded in an amorphous silica (silica glass) matrix. The antiseptic effect was 
demonstrated in vitro (using S. Aureus) and is due to the release of silver ions,95-97 that are not 
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associated to problems of bacterial resistance like in the case of antibiotic treatments. This approach 
is promising but further in vitro tests with the relevant cell types (e.g. orbital fibroblasts) and in vivo 
studies in an animal model have to be performed to draw definite conclusions about the suitability 
of the coating: in fact, the ocular environment is highly complex and several parameters should be 
taken in account, including the solubility of the silica matrix, the interaction of released metal ions 
with the tears and the possible ion-induced eye tissue necrosis. This field of research being very 
new, the existing literature is very scarce, also due to the difficulty in detecting the toxic effect. In 
this regard, Hau and Tuft recently described corneal argyrosis associated with silver nitrate-coated 
cosmetic soft contact lenses that a 67-year-old woman wore for 17 years:98 this is a typical example 
of an apparently unexpected side effect detectable only after many years of follow-up. Matusiewicz 
recently published a comprehensive review article about the toxicity associated to metal ions 
released from orthopaedic and dental implants;99 the provided guidelines to assess and quantify the 
toxic effect could be a valuable starting point and a stimulus to extend such investigations to ocular 
devices. 
As a fascinating promise for the future, it is also instructive to mention the case of retinal implants, 
whose development might benefit by the use of BGs. Despite enormous efforts and advances in 
clinical treatment of eye diseases, there is no established method to prevent or cure degenerative 
processes in eye, such as age-related macular degeneration (ARMD) and retinitis pigmentosa (RP); 
the latter disease can lead to blindness when photoreceptors in the retina are completely 
degenerated. Recent advances in microtechnologies have paved the way to pursue the idea for 
developing an implantable device, commonly referred to as artificial retina, visual prosthesis or 
bionic eye, that can substitute degenerated visual photoreceptors and neural structures for 
stimulating intact neural tissue so that a meaningful visual sensation is obtained. The subretinal 
implant is based on the concept to place a silicon-based microphotodiode array (MPDA) in the 
subretinal space in order to replace the degenerated photoreceptors; a photovoltaic charge is 
generated in each photodiode cell and transferred to the adjacent microelectrode for stimulation of 
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the bipolar cells. An external camera connected to a pair of glasses transmits wirelessly the 
electromagnetic signals to the implanted device. In the late 1990s, a group of German researchers 
manufactured a MPDA on a silicon wafer using complementary metal-oxide semiconductor 
(CMOS) process technology.100 After completion of electrically active structures, a 500-nm thick 
passivation layer consisting of amorphous silicon oxide (silica glass) was applied using 
tetraethylorthosilicate (TEOS) as a precursor. In vivo experiments (rabbits and pigs) revealed a 
decay of the silicon oxide passivation layer and pit corrosion of the underlying silicon for 
implantation periods above 6 months. Therefore, this material has been substituted by stimulation 
microelectrodes made of nanoporous titanium nitride, that demonstrated good biostability over an 
implantation period exceeding 18 months, and other passivation layers, such as polyimide, 
bencocyclobutene (BCB), and parylene C, were selected. Although the choice of amorphous silicon 
oxide as a passivation layer was not the most fortunate, it is an interesting example (at present the 
unique one) about the use of a biocompatibile glass as a thin passivation film in a bionic device 
(retinal implant). In the last two decades, many other types of artificial retinas have proposed by 
several research groups around the world; the interested reader can find a comprehensive picture of 
this topic in a recent review by Ong and Da Cruz.101 The development of functional microdevices 
that fit in the human eye and take over lost biological functions to restore vision is a challenge 
bridging different research fields including materials science, microelectronics and ophthalmology; 
at present, only one retinal implant, Argus II (60 electrodes),102 has received approval for 
commercial use in Europe (2011) and USA by the FDA (2013). In the next few years an increasing 
cooperation among biomaterials scientists, biologists, ophthalmologists and researchers in the 
medical implant industry would be desirable to understand whether BGs and BGCs can play a role 
in the treatment and, hopefully, repair of diseased retina, thus opening new perspectives to further 
improve the patient’s quality of life.  
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CRITERIA AND GUIDELINES FOR SELECTING AND TESTING SUITABLE BG-
BASED MATERIALS FOR OPHTHALMIC APPLICATIONS 
 
Taking the existing literature as a starting point, this section collects some methodological remarks 
in the attempt to provide useful suggestions towards the development of more effective implantable 
BG-based ocular devices, with particular reference to oculo-orbito-plastics (BG/BGC orbital floor 
grafts and orbital implants) and artificial cornea (BG/BGC keratoprosthetic skirt). 
 
Design concept and implants fabrication 
 
First, the ocular implant specifications, such as size, shape, pores features and possible need for 
bioresorption, have to be defined. Implant geometry can be customized on the basis of the patient’s 
anatomy evaluated through CT scanning and/or MRI. Open and highly interconnected 
macroporosity would be a desirable characteristic for all the three types of implants mentioned 
above in order to allow cell invasion in vivo and new tissue in-growth; with regard to BG orbital 
floor grafts, at present only pore-free melt-derived plates were produced and successfully 
experimented in human patients.37-41 Looking at the future, porous implants for the repair of orbital 
bone fractures should exhibit pore size in the 100-600 µm range, as recommended for BG-based 
bone tissue engineering scaffolds.103 Pores within 300-700 µm should be achieved in the case of BG 
porous orbital implants, taking the pore characteristics of the commonly used devices (HA, PE and 
alumina porous spheres17,32,104) as a starting point. Pore diameter ranging from 50 to 150 µm105 is 
adequate to allow keratocytes invasion and proliferation within a BG keratoprosthetic skirt. As to 
the solubility after contact with biological fluids, in vivo resorption can be desirable in the case of 
orbital floor grafts (the BG implant progressively dissolves and is replaced by newly formed bone 
tissue) but it should be avoided for orbital implants and artificial cornea.  
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BG composition has to be designed by carefully selecting the amount and ratio of the different 
constituent oxides. This is a crucial stage as BG formulation affects the physico-chemical and 
biological properties of the final material. If a soluble material is pursued (as in the case of orbital 
floor grafts), phosphate glasses can be chosen, otherwise silicate BGs with high SiO2 content 
(typically above 50 mol.%) should be considered. Additional metal oxides can be introduced in 
small amounts into the BG to finely tune its bioactive properties upon the release of appropriate 
ions: for instance, CuO can be considered in the case of orbital implants as Cu2+ is known to have 
an angiogenetic effect and could stimulate implant fibrovascularization, as suggested by Ye et al.46     
The most appropriate technique for implant fabrication has to be chosen/developed on the basis of 
the properties required for each specific application (e.g. adequate pore size allowing relevant cells 
to colonize the implant, as mentioned above). Dense BG plates matching the size of bone orbital 
fractures can be produced by simple melting-casting route.37-41 If porous BG implants are pursued, a 
number of methods involving the use of pore-forming agents, surfactant-assisted sol-gel methods 
(in the case of MBGs) and rapid prototyping techniques are at the researchers’ disposal. Sintering of 
relatively large glass particles (250-500 µm) without the use of pore formers can be performed (the 
final porosity derives from the interparticle void spaces among the original glass particles).61 The 
deposition of a thin BG coating on a substrate ocular device with adequate morpho-structural 
characteristics in order to impart it a specific added value (e.g. antibacterial effect46,94) is a valuable 
strategy. BGs can be also produced in a nanoporous form, i.e. sol-gel glasses, characterized by an 
intrinsic nanoporosity left by the condensation of the network, or MBGs, in which the ordered 
mesoporosity is due to the use a surfactant. In general, nanoporous BGs have a higher apatite 
forming ability upon contact with biological fluids compared to melt-derived BGs due to the higher 
exposed surface available for ion-exchange processes: this could be an important added values if 
BGs are addressed top orbital bone repair. Mesopores could be also exploited for the uptake and 
subsequent local release of drugs and biomolecules, which could be an interesting extra-
functionality for all the three applications considered in this review.   
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Testing and validation 
 
The morphology, surface features and pores characteristics of the BG-derived implant can be 
assessed by SEM and X-ray micro-CT; XPS and SIMS can be exploited to investigate the surface 
chemistry, and EDS for elemental analysis. The material microstructure should be analysed by 
wide-angle X-ray diffraction (XRD) to assess the presence of crystalline phases developed during 
the thermal treatments applied for implant manufacturing. If MBGs are employed, small-angle 
XRD, TEM and probe molecules sorption techniques (e.g. N2 sorption) are useful to assess the 
mesopores characteristics. Assessment of the surface roughness, which can be performed by 
profilometry or atomic force microscopy (AFM), is particularly important in the case of BG/BGC 
orbital implants, that after implantation could erode the patient’s conjunctiva.  
In vitro tests without cells for preliminary assessment of BG solubility and ion release kinetics in 
appropriate media (e.g. artificial aqueous humour60), as well as BG-induced pH variations, are of 
utmost importance to validate the materials in the light of the implant specifications. As BGs and 
BGCs are, formally, non-crystalline or partially crystalline ceramics, the standard ISO 10993-14 on 
in vitro testing of bioceramics59 can be used as a valuable guideline.58 Dissolution studies at 
different pH values can provide useful data to mimic what happens during implant infections.106 In 
the case of BGs/BGCs for orbital floor repair, where the formation of a surface apatite layer after 
contact with biological fluids is a key goal, FT-IR, XRD, SEM and EDS are all valuable techniques 
to assess the presence of this new phase. If the ocular implant comprises MBGs hosting therapeutic 
agents into the mesopores, drug uptake and release tests should be performed. 
In vitro cytotoxicity testing with appropriate cell types should be commonly recognized as a key 
eliminatory criterion in the selection of BGs/BGCs for ocular applications. Such tests are useful 
because they avoid unnecessary, time-consuming and expensive animal experiments. In this regard, 
Sandeman et al.107 proposed a series of in vitro screening assays for the preliminary selection of 
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(polymeric) biomaterials to be used in the fabrication of artificial corneas. Useful indications for the 
in vitro screening of orbital implant biomaterials were provided by Mawn et al.108 who proposed the 
use of orbital fibroblasts. From a general viewpoint, the standard ISO 10993-5 can be followed for 
in vitro biological tests.109 Advanced studies could be also considered; for example, Tan et al.110 
reported the use of AFM in contact mode to assess the adhesion strength of keratocytes seeded on 
biomaterials for artificial cornea. Antibacterial tests can be performed if the antiseptic effect is one 
of the implant goals.46  
Mechanical testing of BG-based ocular implants is very important, especially considering  that BGs 
and BGCs are brittle materials and, therefore, problems of integrity could occur both during 
implantation and in the postoperative follow-up. A consensus should be achieved on what 
mechanical characteristics to assess and testing methods to apply/adapt; at least the compressive 
strength and elastic modulus should be determined.60 Some authors suggested the use of ex vivo 
(animal) eyes for a preliminary evaluation of the mechanical compatibility between experimental 
keratoprosthetic skirt and corneal tissue.111 From a general viewpoint, it cannot be ignored that BGs 
and BGCs can have a generally good mechanical compatibility with the orbital bone but are 
remarkably stiffer, even if produced in a porous form, than the ocular and intraorbital tissues (Table 
III)75,112-115. Therefore, future research directions could be addressed to the development of more 
compliant ocular biomaterials, such as BG/polymer constructs that have already been successfully 
experimented in ophthalmic surgery14,19,30,51. 
According to the majority of scientists, after extensive in vitro tests with cells there is no recognized 
alternative to pre-clinical animal trials in order to progress the development of biomedical implants 
towards the final stage of clinical trials (human patients). It is worth underlining that the ideal 
implantation site for ophthalmic biomaterials is the eye with its unique physiological and 
microenvironmental characteristics; however, this requires the expertise and availability of an 
ophthalmic surgeon to perform operation, which can represent an additional difficulty in building 
interdisciplinary research teams. In order to simplify the experiments, some authors proposed a 
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rabbit skin subcutaneous model to investigate the in vivo suitability of new keratoprosthetic 
biomaterials.116 Special care should be dedicated to the development of methods to correlate and 
interpret the results deriving from different in vivo studies, the selection of the most appropriate 
animal models and the sequence to follow in performing the experiments. CT scanning and MRI are 
useful to assess tissue in-growth within the implanted porous BG-based ocular devices.   
Finally, sterilization is a crucial issue in view of implant commercialization and safe clinical use. In 
principle, BG-derived ocular implants could be easily sterilized by γ- and β-irradiation, exposition 
to ethylene oxide or UV irradiation without undergoing degradation. Problems with sterilization by 
autoclaving can occur if the BG is susceptible to moisture, like in the case of phosphate glasses that 
are prone to dissolution in aqueous media. Persistence of original properties after sterilization by 
irradiation or autoclaving might be a problem for polymer/BG composites.44,45,60  
 
CONCLUSIONS 
 
The main message of this article – also in order to answer the question posed in the manuscript title 
– is that BGs can be indeed useful and valuable materials for smart applications in ophthalmology. 
At present, however, this potential is still underestimated and the research on such a topic is 
growing very slowly, probably also due to the difficulty of building highly interdisciplinary 
research groups involving the collaboration amongst biomaterials researchers, glass chemists, 
bioengineers, biologists and ophthalmic/maxillofacial surgeons. In general, while BGs and BGCs 
have been extensively investigated for bone and dental repair, there has been relatively little 
research on their application in other medical areas, including ophthalmology. In this regard, it is 
instructive to look at the modern story of biomaterials science: we need to remember that only 40 
years ago the concept of a material that would be able to actively stimulate tissue regeneration 
seemed impossible; this dream became reality with the invention of 45S5 Bioglass® by Prof. Larry 
Hench’s group, but none of the high-impact future applications were forecast when the research 
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began. BGs and BGCs could further improve the performance of ocular implants imparting them 
valuable extra-functionalities. BGs and BGCs can bond to bone promoting new tissue growth, 
which is a key added value for implants devoted to the repair of orbital floor fractures. Through the 
release of appropriate ionic dissolution products, porous BGs and BGCs could stimulate 
fibrovascular in-growth, which is a fundamental characteristic to ensure an adequate motility of 
orbital implants and to reduce the risk of postoperative infections. Porous BGs have been also 
shown to allow and even stimulate keratocytes adhesion and proliferation, which make them 
promising candidates for the development of a new class of skirt keratoprostheses. Looking at the 
future, novel perspectives for eye surgery could raise from the development of BGs with tailorable 
mesoporosity for intraocular/intraorbital drug release, magnetic and radioactive BGs and BGCs for 
eye cancer treatment and BG-based implants whose ion dissolution products can elicit angiogenetic 
and antibacterial effects. 
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Figure legends 
 
FIGURE 1. Implantation of an orbital floor graft via the transantral approach through maxillary 
bone: (a) the graft is introduced under endoscopic guidance; (b) repaired orbital floor. (Legend: 1 = 
maxillary access; 2 = orbital floor fracture; 3 = implanted material repairing the fracture). 
 
FIGURE 2. Sagittal section of a human orbit after enucleation surgery followed by placement of a 
spherical implant that replaces the volume deficit created by eye removal. In this picture the 
extraocular muscles are sutured directly to the implant, which is a common practice in the case of 
malleable polymeric implants (e.g. porous PE); on the contrary, ceramic orbital implant (e.g. HA, 
alumina), being hard and having a rough surface (especially for porous HA), are usually wrapped 
with donor sclera or other natural/synthetic polymeric materials, that are useful for the anchorage of 
the extraocular muscles, make easier the insertion into the anophthalmic socket and limit, acting as 
a physical protective barrier, the risk of postoperative erosion of the patient’s conjunctiva. The 
ocular prosthesis is designed to fit in between the eyelids and the conjunctiva/implant in order to 
mimic the normal appearance of a healthy eye. The optional placement of a peg in the frontal part 
of the orbital implant, that must be drilled after some months from primary surgery, allows direct 
connection with the ocular prosthesis: Use of pegged implants leads to a greater transmission of 
movement of the implant to the artificial aesthetic eye, giving it a more life-like appearance. 
 
Bioactive glasses in ocular surgery 
 
40 
 
FIGURE 3. Schematic perspective view of conventional OOKP (vertical orientation: top - front of 
the eye; bottom - back of the eye). 
 
FIGURE 4. Use of BG plates for the repair of orbital floor defect: (a) CT scan taken 2 years after 
orbital floor reconstruction with a 25 mm × 2 mm S53P4 glass implant (arrow); (b) photograph of a 
BG plate harvested from the orbit in revision surgery after 2 years from primary operation (slight 
resorption of the original margins of the plate was assessed). (Images adapted from Peltola et al.40). 
 
FIGURE 5. MBG-coated porous HA scaffolds for possible use as orbital implants: (a) optical 
image showing the outward appearance of the HA devices before and after undergoing different 
MBG coating (MBG coating with 0, 2 and 5 mol.% of Cu were produced); (b) surface morphology 
of porous HA coated with 5 mol.% Cu-doped MBG and (c) detail of the HA/MBG interface. 
(Images adapted from Ye et al.46). 
 
FIGURE 6. Use of BGs for the production of experimental synthetic OOKP: (a); detail of the 
porous disk of glass-reinforced HA (the porosity of about 22 vol.% was obtained by adding 30 
vol.% poly(vinyl alcohol) as a porogen) (image adapted from Santos et al.58); (b) and (c) 
PMMA/BG composite skirt around the optical PMMA cylinder (images adapted from Laattala et 
al.60).  
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TABLE I. Overview of the BG and BGC Implants That Have Been Clinically Used or Suggested as Experimental Biomaterials in Ocular 
Surgery. 
Application Material and type of implants Recipienta Remarks References 
Eye orbit floor repair Cast curved plates of S53P4 glass HP Slowly resorbable. 37-41 
Orbital implants Porous glass-ceramic sphere (unknown glass-
ceramic compositions) 
AM, HP Experimented in rabbits and humans. 42,43 
 BG/PE porous sphere AM, HP Experimented in rabbits and humans. Apparently, 
no significant improvement in implant 
fibrovascularization was observed with respect to 
porous PE. Studies involving a higher number of 
patients are necessary for a more exhaustive 
assessment. Optimization of bioactive glass 
composition could be necessary. 
44,45 
 Cu-containing mesoporous BG coating on 
porous hydroxyapatite implants 
IV Encouraging antibacterial results against S. 
Aureus and E. Coli. 
46 
 BG filler for peg tracts HP Successful repair and re-pegging of porous 
hydroxyapatite implants. 
50 
Keratoprostheses “Ceravital”-based implants HP Concerns about material resorbability caused 
discontinuance of experiments. 
52-55 
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 Bioverit® I and II AM Experimented in rabbits as materials for the 
porous skirt. 
56 
 Bioactive A/W glass-ceramic coating on 
titanium 
AM Used to coat the titanium flange that anchored the 
prosthesis to the host corneal tissue. 
Experimented in rabbits. 
57 
 Glass-reinforced HA porous composites 
(intended use for the keratoprosthetic skirt) 
IV Encouraging results with human dermal 
fibroblasts. Degradation studies in biological 
media at different pH were carried out. 
58 
 BG/PMMA composite skirts - No biological tests with cells have been carried 
out yet. Decrease of mechanical properties due to 
glass particles dissolution is an issue to be taken 
onto account. 
60 
 BG porous skirts (1-98 and 28-04 glasses) IV Encouraging results with keratocytes. 61 
 BGC disk (intended use for the 
keratoprosthetic skirt) 
AM Experimented in rabbits. The material was found 
unsuitable. 
62 
a
 HP = human patients; AM = animal model only; IV = in vitro tests only. 
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TABLE II. Main Added Values That Can Be Provided by BG/BGC Ocular Implants With Respect to Existing Solutions. 
Feature Provided by currently-used materials? a Improvement provided by BGs/BGCs 
Biocompatibility Yes, at present it is recognized as a pre-condition for clinical 
applications.  
BGs and BGCs are biocompatible and well-tolerated by the 
body under appropriate design of glass composition.  
Ease of processing/shaping Yes; a number of implant shapes/sizes are available on the 
marketplace. Problems of brittleness can occur with porous HA 
plates for OF.  
In principle, BGs and BGCs have the same problems of 
brittleness of ceramics. They have higher versatility with respect 
to crystalline ceramics such as HA and alumina: for instance, 
BGs can be produced by melting-casting. Furthermore, porous 
BG scaffolds are usually mechanically stronger than porous HA 
(better sintering), which can helpful to easily shape and contour 
the implant at the time of surgery, if necessary.   
Open porosity Yes Yes. Besides an interconnected macroporosity, a nano-scale 
porosity (e.g. sol-gel glasses, mesoporous BG) can be 
introduced by using appropriate synthesis routes to impart extra-
functionalities to the implant (e.g. drug uptake/release).  
Solubility Usually not, except for the absorbable polymeric implants 
sometimes used for OF. Absorption of the autologous skirt in 
the case of Strampelli’s OOKP is an undesired event. Note that 
solubility can be a desired option in the case of OF, but should 
be avoided for OI and KP. 
BGs and BGCs with different solubility can be produced 
depending on the oxide formulation.  
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Bone in-growth (for OF only) It depends on the used materials; for instance, yes in the case of 
porous HA, not in the case of porous PE (only vascular in-
growth is allowed).  
Yes. Glass bioactivity can be further enhanced by the presence 
of a nano-scale porosity (sol-gel and mesoporous BGs). 
Fibrovascularization (for OI only) Yes, it is allowed in porous implants (“angioconductive” 
ability).  
Angioinduction could be obtained if the glass is doped with 
appropriate metal ions (e.g. Cu2+). 
Keratocytes colonization (for KP only) It is allowed, but it can be difficult in some cases. Yes, early results are promising. 
Antibacterial properties Not. Yes, if the glass is doped with appropriate metal ions (e.g. Ag+). 
Structural integrity Usually yes; some problems with porous HA plates for OF 
(upon implantation). 
Yes, the mechanical strength can be properly tailored acting on 
glass composition. 
a
 Just to provide the reader a very short overview, the most routinely used materials in ocular surgery for orbital floor repair (OF), orbital implants (OI) and keratoprostheses (KP) 
are the following: autologous bone, porous HA, a number of permanent/absorbable porous/non-porous polymers (including the widely-used porous PE), titanium meshes are used 
for OF16; porous HA, PE and alumina spheres, silicone and PMMA solid spheres, and other PMMA implants of more complex design are used for OI17,31; in the case of KP, 
PMMA (more rarely a transparent hydrogel) is used for the optical core whereas the skirt is made of porous polymers or autologous tooth/bone laminate (Strampelli’s OOKP)19.  
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TABLE III. Comparison Between the Mechanical Properties of Selected Ocular Tissues and Those of BGs (45S5 Bioglass® Was Chosen as 
a Representative Material).   
Material/tissue Compressive strength (MPa) Tensile strength (MPa) Elastic modulus (MPa) References 
45S5 Bioglass® 500 42 35000 112 
Porous 45S5 Bioglass® 
(85-90 vol.% porosity) 
0.2-0.4 0.01-0.02 1570 75,113,114 
Human cortical bone 130-180 50-150 12000-18000 112 
Human cancellous bone 4-12 - 100-500 112 
Human cornea - 3.8 0.2-20 115 
Human sclera - - 2-11 115  
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Fig. 6 
 
